India's Pharma Industry Faces Supply Challenges Despite Duty Waiver

Original: Pharma feels supply pain despite duty relief

The Economic Times•Apr 2, 20263 min

In a Nutshell

India's pharmaceutical industry continues to struggle with supply chain disruptions caused by the conflict in West Asia, despite the government's temporary customs duty waiver on over 40 petrochemical products until June 30. Experts emphasize that securing timely supplies remains the primary challenge, overshadowing the benefits of the duty relief.

Key Points

01The Indian government has waived customs duties on over 40 petrochemical products until June 30.
02Supply chain disruptions from the West Asia conflict pose significant challenges for the pharmaceutical industry.
03Experts highlight that timely movement of supplies is a greater concern than duty relief.
04The restoration of the Remission of Duties and Taxes on Exported Products (RoDTEP) scheme is expected to enhance export competitiveness.
05Shipping disruptions in critical trade routes are affecting delivery timelines for pharmaceutical manufacturers.

In-Article Ad

Full Summary

The Indian pharmaceutical industry is grappling with supply chain challenges exacerbated by the ongoing conflict in West Asia, despite a recent government decision to waive customs duties on over 40 petrochemical products until June 30. Industry experts, including Mehul Shah, emphasize that while the duty waiver offers some cost relief, the primary hurdle lies in securing timely supplies and their movement. The declaration of force majeure by Saudi chemical giant SABIC on methanol and styrene highlights the industry's concerns over supply stability. Furthermore, disruptions in shipping routes, particularly through the Strait of Hormuz, have led to significant delays, impacting production timelines. The chairman of the Pharmaceuticals Export Promotion Council of India, Namit Joshi, noted that the benefits of the duty waiver would be limited unless exporting nations maintain their invoicing prices. In addition, the recent restoration of the Remission of Duties and Taxes on Exported Products (RoDTEP) scheme to its previous level has been welcomed by industry leaders, who believe it will enhance the global competitiveness of Indian medical devices and pharmaceutical exports.

Key Figures

40

Number of petrochemical products with waived customs duties

June 30

Deadline for the customs duty waiver

50%

Previous reduction in RoDTEP rates before restoration

In-Article Ad

Why It Matters

The duty waiver aims to alleviate inflationary pressures on the pharmaceutical and medical devices sectors, potentially leading to lower costs for healthcare providers and patients.

Who is affected

pharmaceutical manufacturers, medical device producers, healthcare providers, and patients

What to know

Industry stakeholders should monitor supply chain developments and advocate for stable invoicing prices from exporting nations.

FAQ

The waiver covers over 40 critical petrochemical products, including anhydrous ammonia, methanol, styrene, and polymers like PVC and PET chips.

The conflict has disrupted shipping routes and supply chains, particularly affecting the timely delivery of essential petrochemical inputs needed for pharmaceutical production.

✦